Yang J D, Gecik P, Collins A, Czarnecki S, Hsu H H, Lasdun A, Sundaram R, Muthukumar G, Silberklang M
Enzon, Inc., 20 Kingsbridge Road, Piscataway, New Jersey 08854-3969.
Biotechnol Bioeng. 1996 Dec 20;52(6):696-706. doi: 10.1002/(SICI)1097-0290(19961220)52:6<696::AID-BIT7>3.0.CO;2-J.
We have developed a serum-free cell culture process utilizing a recombinant baculovirus (AcNPV) expression vector to infect Trichoplusia ni insect cells for the production of the human lysosomal enzyme, glucocerebrosidase. The enzyme, which is harvested as a secreted protein in this process, can serve as a replacement therapy for the genetic deficiency Gaucher disease. In the course of pilot scale-up of a batch glucocerebrosidase process from 25-mL working volume shaker flask units to 25-L working volume stirred bioreactor units, a semi-empirical model was developed for the rational determination of scaleable process parameters, including host cell density at infection, multiplicity of infection (MOI), and harvest time. A key assumption of the model is that maximum protein production is limited by the serum-free medium's nutritional capacity, which can, in turn, be determined from the growth of uninfected cells. For the host cell/medium combination used in this study, the nutritional limit was determined to be 1.3 x 10(7) to 1.7 x 10(7) viable-cell-days/mL. Based on this, the model predicts that optimal protein expression is consistent with a 4-day batch process where the host cell density at the time of infection is 1.5 x 10(6) to 2.0 x 10(6) cells/mL and the MOI is 0.09-0.3. These parameters were empirically confirmed to give the highest achievable batch product yield, first in shaker flasks and then at larger scales. The low MOI allows at least one population doubling to take place post viral addition, so that the effective infected cell density producing product generally exceeds 4 x 10(6) cells/mL. It was also interesting to note that this process consistently achieved the same level of maximum protein production at the 25-L bioreactor scale in 4 days compared to 5 days at the shaker flask scale. This may be attributable to better control of the culture environment in the bioreactor. Unlike some other lepidopteran insect cells, such as Sf-9, T. ni cells were found to produce significant levels of the inhibitory metabolites ammonia and lactate. Our results suggest that reduction and/or removal of inhibitory metabolites might be beneficial for infection of high-density cultures of these cells and might also facilitate application of more sophisticated culture strategies, including fed-batch. (c) 1996 John Wiley & Sons, Inc.
我们开发了一种无血清细胞培养工艺,利用重组杆状病毒(AcNPV)表达载体感染粉纹夜蛾昆虫细胞,用于生产人溶酶体酶葡萄糖脑苷脂酶。在此过程中,该酶作为分泌蛋白收获,可作为戈谢病基因缺陷的替代疗法。在将葡萄糖脑苷脂酶分批工艺从中试规模从25 mL工作体积摇瓶单元扩大到25 L工作体积搅拌生物反应器单元的过程中,开发了一个半经验模型,用于合理确定可扩大规模的工艺参数,包括感染时的宿主细胞密度、感染复数(MOI)和收获时间。该模型的一个关键假设是,最大蛋白质产量受无血清培养基营养能力的限制,而无血清培养基的营养能力又可根据未感染细胞的生长情况来确定。对于本研究中使用的宿主细胞/培养基组合,营养极限确定为1.3×10⁷至1.7×10⁷活细胞·天/mL。基于此,该模型预测最佳蛋白质表达与4天分批工艺一致,其中感染时的宿主细胞密度为1.5×10⁶至2.0×10⁶个细胞/mL,MOI为0.09 - 0.3。这些参数经实验证实可获得最高的分批产品产量,首先在摇瓶中,然后在更大规模上。低MOI允许在添加病毒后至少发生一次群体倍增,因此产生产品的有效感染细胞密度通常超过4×10⁶个细胞/mL。还值得注意的是,与摇瓶规模的5天相比,该工艺在25 L生物反应器规模下4天内始终能达到相同水平的最大蛋白质产量。这可能归因于生物反应器中培养环境的更好控制。与其他一些鳞翅目昆虫细胞(如Sf - 9)不同,发现粉纹夜蛾细胞会产生大量抑制性代谢物氨和乳酸。我们的结果表明,减少和/或去除抑制性代谢物可能有利于这些细胞高密度培养的感染,也可能有助于应用更复杂的培养策略,包括补料分批培养。(c)1996约翰威立父子公司